First Time Loading...

Abcellera Biologics Inc
NASDAQ:ABCL

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
NASDAQ:ABCL
Watchlist
Price: 4.11 USD 1.99% Market Closed
Updated: May 7, 2024

Profitability Summary

33/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Abcellera Biologics Inc

Revenue
38m USD
Operating Expenses
-275.2m USD
Operating Income
-237.2m USD
Other Expenses
90.8m USD
Net Income
-146.4m USD

Margins Comparison
Abcellera Biologics Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
CA
Abcellera Biologics Inc
NASDAQ:ABCL
1.2B USD
-624%
-385%
US
Thermo Fisher Scientific Inc
NYSE:TMO
221.8B USD
17%
14%
US
Danaher Corp
NYSE:DHR
183.2B USD
22%
18%
CH
Lonza Group AG
SIX:LONN
37.4B CHF
20%
10%
US
Agilent Technologies Inc
NYSE:A
41.2B USD
19%
18%
US
IQVIA Holdings Inc
NYSE:IQV
41.2B USD
14%
9%
KR
Samsung Biologics Co Ltd
KRX:207940
55.9T KRW
30%
23%
US
West Pharmaceutical Services Inc
NYSE:WST
26.8B USD
23%
19%
US
Mettler-Toledo International Inc
NYSE:MTD
26.9B USD
29%
21%
IE
ICON PLC
NASDAQ:ICLR
26.1B USD
13%
8%
FR
Sartorius Stedim Biotech SA
PAR:DIM
19B EUR
15%
9%
Country CA
Market Cap 1.2B USD
Operating Margin
-624%
Net Margin
-385%
Country US
Market Cap 221.8B USD
Operating Margin
17%
Net Margin
14%
Country US
Market Cap 183.2B USD
Operating Margin
22%
Net Margin
18%
Country CH
Market Cap 37.4B CHF
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 41.2B USD
Operating Margin
19%
Net Margin
18%
Country US
Market Cap 41.2B USD
Operating Margin
14%
Net Margin
9%
Country KR
Market Cap 55.9T KRW
Operating Margin
30%
Net Margin
23%
Country US
Market Cap 26.8B USD
Operating Margin
23%
Net Margin
19%
Country US
Market Cap 26.9B USD
Operating Margin
29%
Net Margin
21%
Country IE
Market Cap 26.1B USD
Operating Margin
13%
Net Margin
8%
Country FR
Market Cap 19B EUR
Operating Margin
15%
Net Margin
9%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Abcellera Biologics Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CA
Abcellera Biologics Inc
NASDAQ:ABCL
1.2B USD
-12%
-10%
-17%
-30%
US
Thermo Fisher Scientific Inc
NYSE:TMO
221.8B USD
13%
6%
9%
8%
US
Danaher Corp
NYSE:DHR
183.2B USD
16%
10%
12%
10%
CH
Lonza Group AG
SIX:LONN
37.4B CHF
7%
4%
9%
8%
US
Agilent Technologies Inc
NYSE:A
41.2B USD
21%
11%
14%
14%
US
IQVIA Holdings Inc
NYSE:IQV
41.2B USD
23%
5%
10%
9%
KR
Samsung Biologics Co Ltd
KRX:207940
55.9T KRW
9%
5%
9%
6%
US
West Pharmaceutical Services Inc
NYSE:WST
26.8B USD
21%
16%
22%
20%
US
Mettler-Toledo International Inc
NYSE:MTD
26.9B USD
-1 261%
23%
48%
28%
IE
ICON PLC
NASDAQ:ICLR
26.1B USD
8%
4%
8%
6%
FR
Sartorius Stedim Biotech SA
PAR:DIM
19B EUR
8%
4%
7%
5%
Country CA
Market Cap 1.2B USD
ROE
-12%
ROA
-10%
ROCE
-17%
ROIC
-30%
Country US
Market Cap 221.8B USD
ROE
13%
ROA
6%
ROCE
9%
ROIC
8%
Country US
Market Cap 183.2B USD
ROE
16%
ROA
10%
ROCE
12%
ROIC
10%
Country CH
Market Cap 37.4B CHF
ROE
7%
ROA
4%
ROCE
9%
ROIC
8%
Country US
Market Cap 41.2B USD
ROE
21%
ROA
11%
ROCE
14%
ROIC
14%
Country US
Market Cap 41.2B USD
ROE
23%
ROA
5%
ROCE
10%
ROIC
9%
Country KR
Market Cap 55.9T KRW
ROE
9%
ROA
5%
ROCE
9%
ROIC
6%
Country US
Market Cap 26.8B USD
ROE
21%
ROA
16%
ROCE
22%
ROIC
20%
Country US
Market Cap 26.9B USD
ROE
-1 261%
ROA
23%
ROCE
48%
ROIC
28%
Country IE
Market Cap 26.1B USD
ROE
8%
ROA
4%
ROCE
8%
ROIC
6%
Country FR
Market Cap 19B EUR
ROE
8%
ROA
4%
ROCE
7%
ROIC
5%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More